Postattachment Neutralization of a Primary Strain of HIV Type 1 in Peripheral Blood Mononuclear Cells Is Mediated by CD4-Specific Antibodies But Not by a Glycoprotein 120-Specific Antibody that Gives Potent Standard Neutralization

No abstract is available for this paper.

• Publication year

  2001

• Venue

  AIDS Research and Human Retroviruses

• Publication date

  2001-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/088922201753342059PMID 11779352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1.

  2000cited by this paper
• Anti-Cell Antibodies in Exposed Seronegative Individuals with HIV Type 1-Neutralizing Activity

  2000cited by this paper
• Fusion-competent vaccines: broad neutralization of primary isolates of HIV.

  1999cited by this paper
• Properties and mechanism of action of a 17 amino acid, V3 loop-specific microantibody that binds to and neutralizes human immunodeficiency virus type 1 virions.

  1999cited by this paper
• Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study

  1999cited by this paper
• Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans

  1998cited by this paper
• Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41

  1998cited by this paper
• The acquisition of host-encoded proteins by nascent HIV-1.

  1998cited by this paper
• Cellular proteins in HIV virions

  1997cited by this paper
• A human IgG1 (b12) specific for the CD4 binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event.

  1997cited by this paper
• Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization

  1997cited by this paper
• Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.

  1997cited by this paper
• Conformational transitions in CD4 due to complexation with HIV envelope glycoprotein gp120.

  1997cited by this paper
• Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals

  1996cited by this paper
• Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp 120: identification of a very early fusion-independent event as a neutralization target.

  1996cited by this paper
• Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.

  1996cited by this paper
• An antibody that binds domain 1 of CD4 inhibits replication of HIV-1, but not HTLV-I, in a CD4-positive/p56lck-negative HTLV-I-transformed cell line.

  1996cited by this paper
• Inhibition of human immunodeficiency virus type 1 production in infected peripheral blood mononuclear cells by human leukocyte antigen class I-specific antibodies: evidence for a novel antiviral mechanism

  1996cited by this paper
• Update on the neutralisation of animal viruses

  1995cited by this paper
• Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site

  1995cited by this paper
• The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4

  1995cited by this paper
• Neutralization of respiratory syncytial virus after cell attachment

  1995cited by this paper
• Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4

  1995cited by this paper
• Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

  1994cited by this paper
• Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1

  1994cited by this paper
• Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases

  1994cited by this paper
• An antibody that binds the immunoglobulin CDR3‐like region of the CD4 molecule inhibits provirus transcription in HIV‐infected T cells.

  1993cited by this paper
• Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture

  1993cited by this paper
• Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.

  1993cited by this paper
• Postabsorption neutralization of poliovirus

  1993cited by this paper
• Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.

  1993cited by this paper
• The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.

  1992influential reference
• Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody

  1992cited by this paper
• Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry.

  1992cited by this paper
• Neutralizing mechanisms of two human monoclonal antibodies against human cytomegalovirus glycoprotein 130/55.

  1992cited by this paper
• A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

  1991cited by this paper
• Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration.

  1991cited by this paper
• Immunization of simian immunodeficiency virus-infected rhesus monkeys with soluble human CD4 elicits an antiviral response.

  1991cited by this paper
• Soluble human CD4 elicits an antibody response in rhesus monkeys that inhibits simian immunodeficiency virus replication.

  1991cited by this paper
• Anti‐HLA antigen class I heavy chain monoclonal antibodies inhibit human immunodeficiency virus production by peripheral blood mononuclear cells

  1991cited by this paper
• Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus.

  1990cited by this paper
• Analysis of the site in CD4 that binds to the HIV envelope glycoprotein.

  1990cited by this paper
• An early postinfection signal mediated by monoclonal anti-beta 2 microglobulin antibody is responsible for delayed production of human immunodeficiency virus type 1 in peripheral blood mononuclear cells

  1990cited by this paper
• HIV requires multiple gp120 molecules for CD4-mediated infection

  1990cited by this paper
• Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding

  1990cited by this paper
• Identification of the residues in human CD4 critical for the binding of HIV.

  1989cited by this paper
• Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding

  1988cited by this paper
• Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.

  1988cited by this paper
• Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies.

  1987cited by this paper
• A new mechanism for the neutralization of enveloped viruses by antiviral antibody

  1986cited by this paper
• Newcastle disease virus: the effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants.

  1984cited by this paper
• Influenza A virus interaction with murine lymphocytes. I. The influence of influenza virus A/Japan 305 (H2N2) on the pattern of migration of recirculating lymphocytes.

  1976cited by this paper

• Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV‐1 Env Clustering

  2020cites this paper
• Anti-CD4: An Alternative Way to Inhibit HIV Infection

  2016cites this paper
• Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.

  2015cites this paper
• Time Frames for Neutralization during the Human Immunodeficiency Virus Type 1 Entry Phase, as Monitored in Synchronously Infected Cell Cultures

  2007cites this paper
• Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120

  2006cites this paper
• An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion.

  2005cites this paper
• The complex antigenicity of a small external region of the C‐terminal tail of the HIV‐1 gp41 envelope protein: a lesson in epitope analysis

  2005cites this paper
• Multiple Interactions across the Surface of the gp120 Core Structure Determine the Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1

  2003cites this paper
• A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny.

  2003cites this paper
• Polyclonal Immunoglobulin G from Patients Neutralizes Human Immunodeficiency Virus Type 1 Primary Isolates by Binding Free Virions, but without Interfering with an Initial CD4-Independent Attachment of the Virus to Primary Blood Mononuclear Cells

  2003cites this paper
• Anti-Cell Antibodies in Exposed Seronegative Individuals with HIV Type 1-Neutralizing Activity

  2000cites this paper